Segall Bryant & Hamill LLC grew its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 137.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 72,117 shares of the company's stock after purchasing an additional 41,739 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.08% of Myriad Genetics worth $989,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in MYGN. Point72 Hong Kong Ltd purchased a new stake in Myriad Genetics during the 3rd quarter worth $32,000. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Myriad Genetics by 43.8% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company's stock valued at $132,000 after acquiring an additional 1,471 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Myriad Genetics during the third quarter worth about $153,000. KBC Group NV lifted its stake in shares of Myriad Genetics by 132.8% in the fourth quarter. KBC Group NV now owns 5,845 shares of the company's stock worth $80,000 after acquiring an additional 3,334 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new position in Myriad Genetics in the third quarter valued at about $212,000. 99.02% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on the company. Bank of America dropped their price objective on Myriad Genetics from $13.00 to $11.00 and set an "underperform" rating on the stock in a report on Monday, March 3rd. StockNews.com lowered shares of Myriad Genetics from a "buy" rating to a "hold" rating in a research note on Wednesday. Leerink Partners downgraded shares of Myriad Genetics from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $30.00 to $21.00 in a research note on Monday, December 9th. Piper Sandler raised shares of Myriad Genetics from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $11.50 to $12.50 in a report on Wednesday, March 12th. Finally, Craig Hallum initiated coverage on shares of Myriad Genetics in a research note on Wednesday, February 12th. They issued a "buy" rating and a $29.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Myriad Genetics has a consensus rating of "Hold" and an average price target of $20.89.
Get Our Latest Research Report on Myriad Genetics
Myriad Genetics Stock Performance
NASDAQ:MYGN traded up $0.03 during midday trading on Wednesday, reaching $8.87. 95,388 shares of the company traded hands, compared to its average volume of 876,367. The firm has a market capitalization of $809.45 million, a price-to-earnings ratio of -6.81 and a beta of 1.79. The company has a fifty day moving average price of $11.61 and a 200 day moving average price of $16.17. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. Myriad Genetics, Inc. has a twelve month low of $8.53 and a twelve month high of $29.30.
Myriad Genetics (NASDAQ:MYGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. The firm had revenue of $210.60 million for the quarter, compared to analyst estimates of $210.35 million. During the same period last year, the firm posted ($0.12) EPS. On average, analysts expect that Myriad Genetics, Inc. will post -0.3 EPS for the current fiscal year.
About Myriad Genetics
(
Free Report)
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Read More
Before you consider Myriad Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myriad Genetics wasn't on the list.
While Myriad Genetics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
